Esketamine TRD Access Gaps Open Doors for Troches

What Clinicians Are Saying About Esketamine and TRD

A new analysis published in Psychiatric Times examines how clinicians are navigating treatment-resistant depression (TRD) care in 2026, with a particular focus on patient preferences, access barriers, and the role of rapid-acting glutamatergic agents like esketamine (Spravato). The piece highlights how clinicians increasingly recognize that standard antidepressants leave a significant portion of patients without adequate relief — and that the glutamate pathway, targeted by both esketamine and racemic ketamine, represents one of the most meaningful advances in psychiatric treatment in decades.

The analysis focuses on esketamine's FDA-approved indication for TRD and major depressive disorder with acute suicidal ideation or behavior (MDSI). It reinforces esketamine's value in acute crisis settings — particularly for suicidal patients who need rapid symptom relief within hours, not weeks. But it also surfaces a tension that many patients and prescribers already know well: esketamine is expensive, clinic-bound, and governed by a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration and two-hour post-dose observation windows every single session.

The Access Problem Is Real — and It Matters for Troche Patients

The Psychiatric Times piece doesn't shy away from the practical friction surrounding esketamine. Insurance coverage remains inconsistent. Prior authorization hurdles are common. And the logistics of getting to a certified treatment center — twice a week during the induction phase — is a genuine barrier for patients managing work schedules, caregiving responsibilities, transportation challenges, or simply the debilitating fatigue that often accompanies severe depression.

This is precisely where compounded ketamine troches enter the clinical conversation in a meaningful way. While esketamine and racemic ketamine are pharmacologically distinct — esketamine is the S-enantiomer, troches typically use the racemic mixture of both R and S forms — they share the same fundamental mechanism: NMDA receptor antagonism that triggers a glutamatergic cascade, promoting synaptic plasticity and rapid mood changes. The clinical profiles differ, but the underlying biology is closely related.

For patients who are not in acute suicidal crisis but are nonetheless struggling with TRD — and who cannot or do not want to commit to the time, cost, and logistics of twice-weekly clinic visits — a troche-based protocol offers a genuinely different access model. Troches are dispensed by compounding pharmacies, taken at home under prescriber guidance, and absorbed sublingually over 15–20 minutes. The workflow is fundamentally different: less acute, more sustainable, and far more compatible with real life.

Troches vs. Infusions vs. Esketamine: Understanding the Trade-offs

The conversation around ketamine delivery formats is becoming more nuanced, and the Psychiatric Times analysis is a useful prompt to revisit those differences clearly.

IV ketamine infusions deliver the highest bioavailability — nearly 100% — with rapid, predictable plasma concentrations. They're typically used in specialized infusion clinics and are also not covered by most insurance plans. Infusions are powerful and well-studied, but share some of the same access limitations as esketamine in terms of clinic dependency and cost.

Esketamine (Spravato) is a nasal spray administered in a certified healthcare setting. Its FDA approval and acute crisis indication give it a unique clinical role, especially for patients with active suicidal ideation. The REMS program exists specifically because of dissociation and sedation risks — patients cannot drive themselves home. Coverage through insurance is possible but inconsistent and often requires extensive documentation of prior treatment failures.

Compounded ketamine troches sit in a different category entirely. Bioavailability is lower than IV (typically 25–35% sublingually), which means dosing is calibrated differently. But for maintenance treatment, mood stabilization between infusion series, or as a primary at-home protocol for appropriate patients, troches offer something the other formats cannot: continuity. Patients can take them on a consistent schedule — often every few days — without building their week around clinic appointments.

Troches also tend to be significantly more affordable out of pocket, which matters enormously in a treatment landscape where most ketamine options are cash-pay. For patients who have already completed an IV induction series and want to maintain gains, or for those who were never candidates for clinic-based treatment in the first place, troches represent a practical bridge and, in many cases, a long-term solution.

What This Means for Your Treatment Decisions

The growing clinical literature on esketamine — including analyses like this one in Psychiatric Times — is valuable because it keeps ketamine-based therapies in the mainstream psychiatric conversation. It reinforces that glutamatergic treatment is not fringe or experimental; it is an evidence-based priority for one of psychiatry's hardest-to-treat populations.

But the practical implications for patients exploring troches are equally important. The same access barriers that limit esketamine's reach — geography, insurance, time constraints, clinic availability — are exactly the conditions under which troches become clinically relevant. If you're working with a prescriber on a troche protocol, you're participating in a legitimate, physician-supervised treatment approach that addresses TRD through the same neurobiological pathway that has earned esketamine FDA approval and growing clinical endorsement.

The key is appropriate patient selection and good clinical oversight. Troches are not a substitute for emergency psychiatric care — if you are experiencing acute suicidal ideation, that requires immediate clinical intervention. But for the broader TRD population managing persistent, treatment-resistant symptoms in the context of an otherwise stable life, troches offer a meaningful and accessible option that the clinic-only models simply cannot replicate.

Read the original analysis at Psychiatric Times.